Adbry (tralokinumab or tralokinumab-ldrm) is biologic medication known as an interleukin antagonist. It treats moderate-to-severe eczema (also known as atopic dermatitis) in people ages 12 years and older. It's not a first-choice medication, but is only used when topical medications haven't worked well or aren't recommended. Adbry (tralokinumab) is injected under the skin every 2 to 4 weeks, under the guidance of a healthcare professional (HCP). If appropriate, your care team will teach you how to do self-injections at home. Some of the more common side effects of Adbry (tralokinumab) include upper respiratory tract infections.
Moderate-to-severe eczema in people who previously tried or can't use topical medications
Adbry (tralokinumab) is an immune modulator known as an interleukin antagonist. It targets interleukin-13 (IL-13), a protein that's part of your immune system that can cause inflammation. Adbry (tralokinumab) stops IL-13 from working. This lowers inflammation in your skin to help treat symptoms of eczema or atopic dermatitis, such as inflammation and itchiness of the skin.
Source: DailyMed
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
Works well to treat moderate-to-severe eczema
Given every 2 to 4 weeks
Available as prefilled syringes
Can be stored at room temperature for 2 weeks, making it convenient for traveling
Can't be used in children younger than 12 years old
Only available as an injection under the skin
Might need to give yourself 2 separate injections per dose (and 4 injections for the loading dose)
Doesn't cure eczema
Tell your healthcare professional (HCP) or pharmacist that you're taking Adbry (tralokinumab) before receiving any vaccines. This is because you shouldn't receive live vaccines, because it's not known if Adbry (tralokinumab) affects your immune system and raises your risk of infection from the vaccine.
Ask your dermatologist if you still need to take any other medications for eczema when you start Adbry (tralokinumab). They might ask you to also use a topical steroid or topical calcineurin inhibitor, depending on how severe your symptoms are.
Let your dermatologist know if you become pregnant while using Adbry (tralokinumab). Adbry (tralokinumab) hasn't been well-studied in human pregnancy, so it's unclear whether you should continue this medication. Your dermatologist can talk with you about the benefits and risks of continuing Adbry (tralokinumab), as well as about other options for treating eczema during pregnancy.
Tips for using Adbry (tralokinumab) at home
Make sure you know how to give yourself the injection to avoid hurting yourself or accidentally wasting any of the medication. Carefully review the instructions for use or video. Let your dermatologist or pharmacist know if you have any questions.
Store Adbry (tralokinumab) prefilled syringes in the refrigerator in the original container away from light. Don't freeze them. When it's time for your dose, take Adbry (tralokinumab) out of the refrigerator and allow it to warm up to room temperature (takes about 30 minutes). Don't try to warm up the syringe any other way (e.g., microwave, run under hot water, leave in sunlight), because this could damage the medication.
If you're traveling and don't have access to a refrigerator, Adbry (tralokinumab) can be kept at room temperature for up to 2 weeks. Don't place the medication back into a refrigerator after it's reached room temperature.
Always check to make sure the medication is clear and colorless to pale yellow before using it. If it's cloudy, discolored, has many particles (solid pieces), or the syringe cap is missing, don't use it. Contact your HCP or pharmacist to see if it's possible to get a replacement.
Inject Adbry (tralokinumab) under your skin in either your stomach (at least 2 inches away from the belly button) or thighs. Caregivers can also help inject the medication under the skin of your upper arm. Never inject the medication into the muscle, veins, or through clothes.
Each prefilled syringe contains 150 mg of Adbry (tralokinumab). This means you'll need four injections if your dose is 600 mg, or two injections if your dose is 300 mg. Inject each syringe during your dose at different sites within the same body area. For your next dose, choose different injection sites from those you used last time. Don't inject into tender, damaged, bruised, or scarred skin so you don't hurt yourself or damage the skin even more.
Throw away Adbry (tralokinumab) syringes after each use, even if you see any leftover medication inside. The medication doesn't contain any preservatives to keep germs and bacteria out once you open it.
After your injection, place your syringe in a sharps container or a heavy-duty plastic container (e.g., empty milk carton, laundry detergent bottle) to lower the risk of needle-stick injuries. Don't throw away syringes, needles, or On-Body Injectors into your trash can. Visit the FDA's website for guidance on how to throw it away safely your sharps container in your specific state.
Adbry (tralokinumab) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Serious allergic reactions to Adbry (tralokinumab) are possible, including life-threatening reactions like anaphylaxis (e.g., closing of the throat). If you notice a choking sensation, difficulty breathing, dizziness, sweating, nausea, or swelling around your eyes, lips, or tongue while taking Adbry (tralokinumab), get medical attention right away.
Adbry (tralokinumab) can cause pink eye and eye inflammation. These eye problems eventually went away in most people. Contact your dermatologist or optometrist if you notice changes in vision, blurry vision, eye irritation, or itchy or watery eyes while taking Adbry (tralokinumab).
It's not completely known if Adbry (tralokinumab) can weaken your immune system's response against certain infections, such as parasitic infections. Let your dermatologist know if you have an infection before starting this medication so you can get treated for it first. If you develop an infection during Adbry (tralokinumab) therapy and antiparasitic medications don't help, you might have to stop taking Adbry (tralokinumab) until your infection goes away.
Avoid getting live vaccines because it's not known whether they're safe to get while you're taking Adbry (tralokinumab). Examples of live vaccines include Varivax (chickenpox vaccine) and MMR (measles, mumps, and rubella vaccine). It's best to be up to date on all your vaccines before you start Adbry (tralokinumab). Let your HCP or pharmacist know that you're taking Adbry (tralokinumab) before you get any vaccines.
Adbry (tralokinumab) is injected under skin into the thigh, stomach, or upper arm (if given by a caregiver).
Adults: The typical dose is 600 mg injected under the skin as a single dose, then 300 mg injected every 2 weeks.
Children (ages 12 years and older): The typical dose is 300 mg injected under the skin as a single dose, then 150 mg injected every 2 weeks.
After 4 months of treatment, your dermatologist might ask you to inject Adbry (tralokinumab) 300 mg once a month. This is only an option for people who weigh less than 220 pounds and have achieved clear or almost clear skin.
Your dermatologist might prescribe Adbry (tralokinumab) along with topical corticosteroids and topical calcineurin inhibitors.
Moderate-to-severe eczema in people who previously tried or can't use topical medications
Moderate-to-severe eczema that isn't well-controlled by other topical medications - adults and children 6 months and older
Add-on treatment for moderate-to-severe asthma - adults and children 6 years and older
Long-term sinus congestion with nasal polyps - adults only
Swollen esophagus (eosinophilic esophagitis) - adults and children 1 year and older
Long-term itchy skin bumps (prurigo nodularis) - adults
By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.
American Academy of Allergy, Asthma & Immunology. (2024). Immunomodulator allergy medications.
Bieber, T. (2020). Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy.
Centers for Disease Control and Prevention. (2024). About parasites.
LEO Pharma Inc. (2023). A step-by-step guide to injecting Adbry® (tralokinumab-ldrm) at home.
LEO Pharma Inc. (2024). Adbry- tralokinumab-ldrm injection, solution [package insert]. DailyMed.
LEO Pharma Inc. (n.d.). Treatment resources & videos.
National Eczema Society. (n.d.). Topical calcineurin inhibitors (TCIs).
U.S. Food and Drug Administration. (2021). Safely using sharps (needles and syringes) at home, at work and on travel.
U.S. Food and Drug Administration. (2023). Drug trials snapshots: Adbry.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.